Faron Pharmaceuticals Oy

AIM:FARN Stock Report

Market Cap: UK£156.9m

Faron Pharmaceuticals Oy Balance Sheet Health

Financial Health criteria checks 6/6

Faron Pharmaceuticals Oy has a total shareholder equity of €1.4M and total debt of €12.4M, which brings its debt-to-equity ratio to 897.6%. Its total assets and total liabilities are €35.5M and €34.1M respectively.

Key information

897.6%

Debt to equity ratio

€12.38m

Debt

Interest coverage ration/a
Cash€29.98m
Equity€1.38m
Total liabilities€34.08m
Total assets€35.46m

Recent financial health updates

Recent updates

Faron Pharmaceuticals Oy's (LON:FARN) Intrinsic Value Is Potentially 74% Above Its Share Price

Aug 02
Faron Pharmaceuticals Oy's (LON:FARN) Intrinsic Value Is Potentially 74% Above Its Share Price

Do Institutions Own Faron Pharmaceuticals Oy (LON:FARN) Shares?

Mar 05
Do Institutions Own Faron Pharmaceuticals Oy (LON:FARN) Shares?

What Type Of Shareholders Make Up Faron Pharmaceuticals Oy's (LON:FARN) Share Registry?

Nov 20
What Type Of Shareholders Make Up Faron Pharmaceuticals Oy's (LON:FARN) Share Registry?

Financial Position Analysis

Short Term Liabilities: FARN's short term assets (€34.0M) exceed its short term liabilities (€23.5M).

Long Term Liabilities: FARN's short term assets (€34.0M) exceed its long term liabilities (€10.6M).


Debt to Equity History and Analysis

Debt Level: FARN has more cash than its total debt.

Reducing Debt: FARN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FARN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: FARN has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 6% each year.


Discover healthy companies